Dark

Check out our API

CMRX
Chimerix, Inc.
stock NASDAQ

Inactive

Apr 17, 2025

8.54USD-0.117%(-0.01)755,560

Pre-market

0.00USD-100.000%(-8.55)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 20, 2022

08:00AM EST Chimerix(NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Mike Andriole, Chief Business and Financial Officer, will present a corporate overview at the B. Riley Virtual Oncology Conference on Thursday, January 27, 2022 at 3:00 p.m. ET. GlobeNewswire Inc

Jan 18, 2022

04:03PM EST Chimerix Announces Publication Of ONC201 Data From Phase 2 Study In Neuroendocrine Tumors In Clinical Cancer Research Benzinga

04:01PM EST Chimerix Announces Publication of Positive ONC201 Data from Phase GlobeNewswire Inc

Jan 3, 2022

04:45PM EST Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 GlobeNewswire Inc

Dec 22, 2021

03:40PM EST Chimerix Sam.gov Site Contract Listing For Co.'s Smallpox Antiviral,' Size Of Contract Not Disclosed Benzinga

07:51AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

06:13AM EST HC Wainwright & Co. Maintains Buy on Chimerix, Raises Price Target to $24 Benzinga

Nov 22, 2021

04:42PM EST 16:41 Monday, November 22, 2021Wedbush (RTTNews) - Wedbush Reiterates Chimerix, Inc. (CMRX) At Outperform With $14 Down From $15 Price Target RTTNews

11:58AM EST HC Wainwright & Co. Maintains Buy on Chimerix, Raises Price Target to $21 Benzinga

Nov 19, 2021

07:03AM EST Chimerix Reports ONC201 Data In Recurrent Diffuse Midline Glioma To Be Presented At Society For Neuro-Oncology Annual Meeting Nov. 20 Benzinga

07:00AM EST Chimerix Announces Positive ONC201 Data in Recurrent H3 GlobeNewswire Inc

Nov 15, 2021

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

Nov 12, 2021

08:00AM EST Chimerix to Present at Jefferies London Healthcare Conference GlobeNewswire Inc

Nov 11, 2021

07:00AM EST Chimerix(NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced upcoming data presentations at theSociety for Neuro-Oncology (SNO) Annual Meeting 2021, which will be held in Boston, MA from November 19-21, 2021. GlobeNewswire Inc

Nov 4, 2021

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

07:28AM EDT Chimerix Q3 EPS $(0.21) Misses $(0.15) Estimate Benzinga

07:21AM EDT Chimerix Reports Data From Efficacy Analysis Of ONC201 In H3 K27M-mutant Glioma Benzinga

07:05AM EDT Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma GlobeNewswire Inc

07:00AM EDT Blinded Independent Central Review (BICR) of ONC201 Cohort Reported 20.0% Objective Response Rate (ORR) by RANO-HGG Criteria GlobeNewswire Inc

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Nov 1, 2021

08:00AM EDT Chimerix(NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix, will present a corporate overview at the Credit Suisse 30th Annual Healthcare Conference onMonday, November 8, 2021at9:40 a.m. ET. GlobeNewswire Inc

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 28, 2021

07:00AM EDT Chimerix to Report Third Quarter 2021 Financial Results and GlobeNewswire Inc

Oct 14, 2021

12:04PM EDT Chimerix Option Alert: Nov 19 $7.5 Calls Sweep (32) near the Ask: 675 @ $0.66 vs 1488 OI; Earnings 11/4 Before Open [est] Ref=$6.29 Benzinga

Sep 15, 2021

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

Sep 7, 2021

07:00AM EDT Chimerix to Present at H.C. Wainwright 23rd Annual Global GlobeNewswire Inc

Aug 27, 2021

05:14PM EDT Return on Capital Employed Insights for Chimerix Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

07:23AM EDT Chimerix Q2 EPS $(0.21) Misses $(0.19) Estimate, Sales $391.00K Miss $480.00K Estimate Benzinga

07:00AM EDT Received U.S. Food and Drug Administration (FDA) Approval for TEMBEXA (brincidofovir) for the Treatment of Smallpox GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 3, 2021

07:00AM EDT Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 10:55 a.m. ET. GlobeNewswire Inc

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 29, 2021

07:00AM EDT Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2021, and to provide an operational update. GlobeNewswire Inc

Jun 7, 2021

06:12AM EDT HC Wainwright & Co. Maintains Buy on Chimerix, Raises Price Target to $19 Benzinga

Jun 4, 2021

02:10PM EDT Chimerix Receives U.S. Food and Drug Administration Approval for GlobeNewswire Inc

May 25, 2021

08:00AM EDT Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix, will present a corporate overview at the Jefferies Virtual Healthcare Conference onTuesday, June 1, 2021at10:00 a.m. ET. GlobeNewswire Inc

May 19, 2021

05:25PM EDT Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021 Benzinga

05:01PM EDT Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming oral and poster presentations at the American Society of Clinical Oncology 2021 Annual Meeting, which will be held virtually June 4-8, 2021. GlobeNewswire Inc

May 13, 2021

07:00AM EDT Chimerix to Present at Cowen and Company 2nd Annual Virtual GlobeNewswire Inc

May 6, 2021

12:48PM EDT HC Wainwright & Co. Maintains Buy on Chimerix, Raises Price Target to $18 Benzinga

10:48AM EDT ChimerixFiles for Potential Mixed Shelf Offering; Size Not Disclosed Benzinga

07:28AM EDT Chimerix Q1 EPS $(1.21) Misses $(0.41) Estimate Benzinga

07:00AM EDT BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 GlobeNewswire Inc

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Apr 29, 2021

10:32AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 29, 2021 Benzinga

08:53AM EDT Maxim Group Initiates Coverage On Chimerix with Buy Rating, Announces Price Target of $20 Benzinga

07:00AM EDT Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2021, and to provide an operational update. GlobeNewswire Inc

Apr 26, 2021

07:00AM EDT Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment ofVicki Vakiener to its Board of Directors, effective immediately.Ms. Vakienercurrently serves as Chief Commercial Officer ofEpizyme Inc. GlobeNewswire Inc

Apr 8, 2021

04:01PM EDT Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held virtually from April 10-15, 2021 and May 17-21, 2021. GlobeNewswire Inc

Mar 31, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021 Benzinga

07:59AM EDT Wedbush Initiates Coverage On Chimerix with Outperform Rating, Announces Price Target of $14 Benzinga

07:58AM EDT Jefferies Initiates Coverage On Chimerix with Buy Rating, Announces Price Target of $21 Benzinga

Mar 2, 2021

07:00AM EST Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright Global Life Sciences Conference made available on Tuesday, March 9, 2021 at 7:00 a.m. ET. GlobeNewswire Inc

Feb 26, 2021

01:45PM EST DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial PR Newswire

Feb 25, 2021

08:50AM EST Chimerix's DSTAT Shows Promising Results In First Cohort Of COVID-19 Study Benzinga

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

07:16AM EST Chimerix Q4 EPS $(0.19) Beats $(0.20) Estimate, Sales $1.10M Beat $1.03M Estimate Benzinga

07:00AM EST Chimerix Reports Promising Topline Results from First Cohort of a GlobeNewswire Inc

07:00AM EST Acquisition of Oncoceutics Adds Late-Stage Precision Oncology Pipeline GlobeNewswire Inc

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 23, 2021

04:45PM EST Point72 Discloses 5% Passive Stake In Chimerix Benzinga

Feb 18, 2021

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

07:00AM EST Chimerix to Report Fourth Quarter and Year End 2020 Financial GlobeNewswire Inc

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Jan 25, 2021

05:44PM EST Chimerix Announces Closing of Public Offering of Common Stock and GlobeNewswire Inc

Jan 22, 2021

07:22AM EST The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa Benzinga

Jan 21, 2021

05:44AM EST Chimerix Priced 11.765M Share Public Offering of Common Stock @$8.50/Share Benzinga

Jan 20, 2021

08:58PM EST Chimerix Prices Underwritten Public Offering Of 11.77 Mln Shares At $8.50/shr RTTNews

08:03PM EST Chimerix Announces Pricing of Public Offering of Common Stock GlobeNewswire Inc

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 19, 2021

04:20PM EST Chimerix Reports $75M Common Stock Offering Benzinga

04:19PM EST Chimerix Announces Proposed $75,000,000 Public Offering of Common GlobeNewswire Inc

Jan 12, 2021

08:16AM EST The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga

Jan 11, 2021

06:10AM EST HC Wainwright & Co. Maintains Buy on Chimerix, Raises Price Target to $16 Benzinga

Jan 8, 2021

02:51PM EST Mid-Afternoon Market Update: Gold Dips 3.5%; Merus Shares Surge Benzinga

12:27PM EST Mid-Day Market Update: Dow Falls 50 Points; Chimerix Shares Spike Higher Benzinga

10:32AM EST Shares of Chimerix, Inc. (CMRX) surged over 60% on Friday morning after the biopharmaceutical company announced acquisition of Oncoceutics to expand pipeline with late-stage oncology program. RTTNews

10:20AM EST Mid-Morning Market Update: Markets Mostly Higher; US Economy Loses 140,000 Jobs In December Benzinga

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

06:07AM EST Chimerix Acquires Oncoceutics For $78M; $39M In Cash And $39M In Stock Benzinga

06:00AM EST Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage GlobeNewswire Inc

Jan 6, 2021

08:00AM EST Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2021 Conference made available on Monday, January 11, 2021 at 7:00 a.m. ET. GlobeNewswire Inc

Dec 18, 2020

07:48AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga

07:45AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data Benzinga

Dec 17, 2020

08:10AM EST The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga

Dec 16, 2020

07:15AM EST The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 7, 2020

07:01AM EST Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox Benzinga

07:00AM EST Chimerix Announces FDA Acceptance of New Drug Application for GlobeNewswire Inc

Dec 1, 2020

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

Nov 5, 2020

07:12AM EST Chimerix Q3 EPS $(0.18) Misses $(0.17) Estimate, Sales $1.61M Beat $960.00K Estimate Benzinga

07:00AM EST Completed Rolling NDA Submissions for Both BCV Tablet and SuspensionFormulations as Medical Countermeasure for Smallpox GlobeNewswire Inc

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

08:59AM EST Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23 Benzinga

Oct 29, 2020

07:00AM EDT Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 5, 2020 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2020, and to provide a business overview. GlobeNewswire Inc

Sep 10, 2020

08:00AM EDT Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September: GlobeNewswire Inc

Aug 20, 2020

01:22PM EDT Chimerx CEO Mike Sherman To Appear On TD Ameritrade Network Benzinga

Aug 10, 2020

07:28AM EDT Recap: Chimerix Q2 Earnings Benzinga

07:08AM EDT Chimerix Q2 EPS $(0.16) Beats $(0.17) Estimate, Sales $1.40M Beat $1.06M Estimate Benzinga

07:00AM EDT Completion of BCV NDA Rolling Submission Planned for Third Quarter 2020 GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 3, 2020

08:00AM EDT Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2020, and to provide a business overview. GlobeNewswire Inc

Jul 29, 2020

11:41AM EDT Chimerix Shares Move Higher After Co. Granted European Patent Titled 'PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF USEFUL AS ANTIVIRAL AGENTS' Benzinga

Share